Gland Pharma Q2 net profit rises 58.29% to ₹290.75 crore
In short
Gland Pharma reported Q2 net profit of ₹290.75 crore, up 58.29% from ₹183.68 crore a year earlier. Revenue rose to ₹1,833.58 crore from ₹1,486.87 crore, and expenses increased to ₹1,471.69 crore.
What the reporting says
Gland Pharma reported a 58.29% rise in consolidated net profit to ₹290.75 crore for the September quarter, according to a regulatory filing. Revenue from operations rose to ₹1,833.58 crore from ₹1,486.87 crore a year earlier, while total expenses increased to ₹1,471.69 crore from ₹1,287.12 crore. The company said the results were driven by strong execution across businesses and also launched four molecules.
Why it matters
Gland Pharma posted a 58.29% rise in consolidated net profit to ₹290.75 crore in the September quarter, while revenue from operations climbed to ₹1,833.58 crore. Total expenses also rose to ₹1,471.69 crore. The company said execution across businesses supported the quarter and noted the launch of four molecules, which is relevant for its operating and product pipeline outlook.